Modelling the impact of colorectal cancer screening strategies: A systematic review and meta-analysis

Figure 1  Flowchart of the selection process.

Figure 2 Summary of findings from pooled analysis of common screening strategies. Screening strategies based on United States Preventive Services Task Force guidelines and the popularity. ¹Screening strategies are presented as screening modality, age to begin-age to end screening, screening interval. ²Lifetime effects compared with no screening. CI: Confidence interval; CRC: Colorectal cancer; CTC: Computed tomography colonography; FIT: Fecal immunochemical test; FS: Flexible sigmoidoscopy; mSEPT9: Methylated Septin 9 DNA blood test; mt-sDNA: Multitarget stool-based DNA; RR: Risk ratio.

Figure 3 Cost-effectiveness analysis of colorectal cancer screening strategies vs no screening. Bar charts depict the number of modelled scenarios-varying in model, screening age and interval-in which each screening strategy was classified as cost-saving (blue), cost-effective (orange), or not cost-effective (gray) according to the original studies’ willingness-to-pay thresholds. A: Presents outcomes under perfect adherence; B: Presents outcomes under realistic adherence. AI: Artificial intelligence; cf-bDNA: Cell-free DNA blood test; CTC: Computed tomography colonography; FIT: Fecal immunochemical test; FOBT: Fecal occult blood testing; FS: Flexible sigmoidoscopy; MRC: MR colonography; mSEPT9: Methylated Septin 9 DNA blood test; mt-sDNA: Multitargeted stool-based DNA; mt-sRNA: Multitarget stool RNA; ngMT-sDNA: Next-generation MT-sDNA; UMT: Urine metabolomic-based test.